Top Markets
#1 Brevis Brevis +35.04%
#2 Keep Network Keep Network +28.96%
#3 Talus Network Talus Network +28.51%
#4 Tung Tung Tung Sahur Tung Tung Tung Sahur +26.94%
#5 MemeCore MemeCore +25.40%
#6 Infinity Ground Infinity Ground +21.91%
#7 Synapse Synapse +21.54%
#8 Cortex Cortex +20.78%
#9 Starpower Starpower +20.19%
#10 Allora Allora +18.82%
Coin of the day
Brevis Brevis
Settings
Language
ENGLISH
Currency
USD
Theme
IntegraGen SA IntegraGen SA

IntegraGen SA

ALINT
Rank in Stocks #19673
IntegraGen SA provides human genome analysis services for academic researcher... IntegraGen SA provides human genome analysis services for academic researcher and life sciences companies in France. Its genomic services include transcriptomics, epigenomics, DNA sequencing, NGS testing for cancer research, and SNP genotyping. The company offers clinical research services, such as clinical grade sequencing and pharmacogenomics; basic and human genetic research; agrigenomic services, including crop and livestock genotyping and high-throughput sequencing for crops and livestock; and microbial genomics services comprising whole-genome microbial sequencing and microbial transcriptomics. It also provides MERCURY, an online biological interpretation tool for oncology intended to assist pathologists and oncologists in transforming raw data obtained through high-throughput sequencing into a molecular report for translational and clinical research use; SIRIUS, a cloud-based software tool that enables researchers to analyze whole genome, whole exome, and gene panel sequencing data; Galileo, a cloud-based app for dynamic exporation of RNA-Seq expression data; and GeCo, a genomic consulting service that offers researchers with access to biostatistics and bioanalytics experts. IntegraGen SA was founded in 2000 and is headquartered in Évry, France. IntegraGen SA is a subsidiary of OncoDNA SA.
Share Price
$0.20876331
Market Cap
$1.38M
Change (1 day)
1.15%
Change (1 year)
-64.84%
Country
FR
Trade IntegraGen SA (ALINT)

Category

Healthcare
Revenue for IntegraGen SA (ALINT)
Revenue in Dec 2025 TTM: $5.89M
According to IntegraGen SA latest financial reports the company's current revenue (TTM) is $5.89M. In 2023 the company made a revenue of $13.86M a decrease compared to the revenue in the year 2022 that was $14.12M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for IntegraGen SA from 2008 to 2026
Revenue at the end of each year
Year Revenue Change
2026 (TTM) $5.89M -34.91%
2024 $9.05M -34.70%
2023 $13.86M -1.87%
2022 $14.12M 9.68%
2021 $12.88M 17.75%
2020 $10.94M 17.72%
2019 $9.29M 16.30%
2018 $7.99M 2.28%
2017 $7.81M 18.34%
2016 $6.60M 5.01%
2015 $6.28M -15.26%
2014 $7.42M -0.36%
2013 $7.44M 19.02%
2012 $6.25M 3.91%
2011 $6.02M 36.01%
2010 $4.43M 9.71%
2009 $4.03M 28.07%
2008 $3.15M 0.00%
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 $52.05B 883,391.72%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.26B 207,933.89%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 $14.92B 253,164.55%
US
UCB SA UCB SA
UCB SA
UCB.BR
 $9.08B 154,074.16%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.29B 106,681.86%
NL